Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 22068254)

1.

Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.

Chan JL, Lutz K, Cochran E, Huang W, Peters Y, Weyer C, Gorden P.

Endocr Pract. 2011 Nov-Dec;17(6):922-32. doi: 10.4158/EP11229.OR.

2.

The liver diseases of lipodystrophy: the long-term effect of leptin treatment.

Safar Zadeh E, Lungu AO, Cochran EK, Brown RJ, Ghany MG, Heller T, Kleiner DE, Gorden P.

J Hepatol. 2013 Jul;59(1):131-7. doi: 10.1016/j.jhep.2013.02.007. Epub 2013 Feb 21.

3.

Long-term efficacy of leptin replacement in patients with generalized lipodystrophy.

Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P.

Diabetes. 2005 Jul;54(7):1994-2002.

4.

Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.

Javor ED, Ghany MG, Cochran EK, Oral EA, DePaoli AM, Premkumar A, Kleiner DE, Gorden P.

Hepatology. 2005 Apr;41(4):753-60.

PMID:
15791619
5.

Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy.

Park JY, Chong AY, Cochran EK, Kleiner DE, Haller MJ, Schatz DA, Gorden P.

J Clin Endocrinol Metab. 2008 Jan;93(1):26-31. Epub 2007 Oct 16.

6.

Leptin-replacement therapy for lipodystrophy.

Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A.

N Engl J Med. 2002 Feb 21;346(8):570-8.

7.

Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes.

Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, Herion D, Kleiner DE, Reynolds J, Premkumar A, Sumner AE, Hoofnagle J, Reitman ML, Taylor SI.

Ann Intern Med. 2000 Aug 15;133(4):263-74.

PMID:
10929166
8.

Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.

Ebihara K, Kusakabe T, Hirata M, Masuzaki H, Miyanaga F, Kobayashi N, Tanaka T, Chusho H, Miyazawa T, Hayashi T, Hosoda K, Ogawa Y, DePaoli AM, Fukushima M, Nakao K.

J Clin Endocrinol Metab. 2007 Feb;92(2):532-41. Epub 2006 Nov 21.

PMID:
17118991
9.

Consequences of stopping and restarting leptin in an adolescent with lipodystrophy.

Kamran F, Rother KI, Cochran E, Safar Zadeh E, Gorden P, Brown RJ.

Horm Res Paediatr. 2012;78(5-6):320-5. doi: 10.1159/000341398. Epub 2012 Sep 4.

10.

Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.

Diker-Cohen T, Cochran E, Gorden P, Brown RJ.

J Clin Endocrinol Metab. 2015 May;100(5):1802-10. doi: 10.1210/jc.2014-4491. Epub 2015 Mar 3.

PMID:
25734254
11.

[Therapy resistant diabetes mellitus and lipodystrophy: leptin therapy leads to improvement].

Jazet IM, Jonker JT, Wijngaarden MA, Lamb H, Smelt AH.

Ned Tijdschr Geneeskd. 2013;157(4):A5482. Review. Dutch.

PMID:
23343738
12.

Lipid regulation in lipodystrophy versus the obesity-associated metabolic syndrome: the dissociation of HDL-C and triglycerides.

Joseph J, Shamburek RD, Cochran EK, Gorden P, Brown RJ.

J Clin Endocrinol Metab. 2014 Sep;99(9):E1676-80. doi: 10.1210/jc.2014-1878. Epub 2014 Jun 13.

13.

Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety.

Simha V, Subramanyam L, Szczepaniak L, Quittner C, Adams-Huet B, Snell P, Garg A.

J Clin Endocrinol Metab. 2012 Mar;97(3):785-92. doi: 10.1210/jc.2011-2229. Epub 2011 Dec 14.

14.

Rationale for leptin-replacement therapy for severe lipodystrophy.

Oral EA, Chan JL.

Endocr Pract. 2010 Mar-Apr;16(2):324-33. doi: 10.4158/EP09155.RA. Review.

PMID:
20061299
15.

Efficacy of leptin therapy in the different forms of human lipodystrophy.

Chong AY, Lupsa BC, Cochran EK, Gorden P.

Diabetologia. 2010 Jan;53(1):27-35. doi: 10.1007/s00125-009-1502-9. Epub 2009 Sep 2.

PMID:
19727665
16.

[Lipodystrophy. Mechanisms, clinical presentation, therapy].

Miehle K, Stumvoll M, Fasshauer M.

Internist (Berl). 2011 Apr;52(4):362, 364-6, 368-70 passim. doi: 10.1007/s00108-010-2711-5. German.

PMID:
21424143
17.

Metreleptin: first global approval.

Chou K, Perry CM.

Drugs. 2013 Jun;73(9):989-97. doi: 10.1007/s40265-013-0074-7. Review.

PMID:
23740412
19.

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.

Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG.

Curr Med Res Opin. 2008 Jan;24(1):275-86.

PMID:
18053320
20.

Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy.

Christensen JD, Lungu AO, Cochran E, Collins MT, Gafni RI, Reynolds JC, Rother KI, Gorden P, Brown RJ.

J Clin Endocrinol Metab. 2014 Aug;99(8):E1493-500. doi: 10.1210/jc.2014-1353. Epub 2014 Jul 29.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk